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Relationship Between Peak Troponin Values and Long-Term Ischemic
Events Among Medically Managed Patients With Acute Coronary
Syndromes
Sarah A. Goldstein, MD; L. Kristin Newby, MD, MHS; Derek D. Cyr, PhD; Megan Neely, PhD; Thomas F. L€uscher, MD; Eileen B. Brown, MD;
Harvey D. White, MB, ChB, DSc; E. Magnus Ohman, MD; Matthew T. Roe, MD, MHS; Christian W. Hamm, MD, PhD
Background-—The relationship between troponin level and outcomes among patients with non-ST-segment elevation ACS is
established, but the relationship of troponin level with long-term outcomes amongmedically managed non-ST-segment elevation ACS
patients receiving contemporary antiplatelet therapy is inadequately deﬁned.
Methods and Results-—In 6763 medically managed non-ST-segment elevation ACS patients randomized in TRILOGY ACS (Targeted
Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) (prasugrel versus clopidogrel),
we examined relationships between categories of peak troponin/upper limit of normal (ULN) ratio within 48 hours of the index
ACS event (4.5 days before randomization) and 30-month outcomes (cardiovascular death, myocardial infarction, or stroke;
cardiovascular death or myocardial infarction; and all-cause death). Patients with peak troponin levels <19ULN were younger, were
more often women, and had lower GRACE risk scores than those in other troponin groups. Those with ratios ≥59ULN were more
frequently smokers but less often had prior myocardial infarction or percutaneous coronary intervention. Diabetes mellitus
prevalence, body mass index, serum creatinine, and hemoglobin were similar across groups. For all end points, statistically
signiﬁcant differences in 30-month event rates were observed between peak troponin categories. The relationship was linear for
30-month mortality (<19ULN, n=1849 [6.2%]; 1 to <39ULN, n=1203 [9.6%]; 3 to <59ULN, n=581 [10.8%]; and ≥59ULN, n=3405
[12.8%]) but plateaued for composite end points beyond peak troponin values ≥39ULN. There was no statistically signiﬁcant
heterogeneity in treatment effect by peak troponin ratio for any end point.
Conclusions-—Among medically managed non-ST-segment elevation ACS patients selected for medical management, there was a
graded relationship between increasing peak troponin and long-term ischemic events but no heterogeneity of treatment effect for
prasugrel versus clopidogrel according to peak troponin.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00699998. ( J Am Heart Assoc. 2017;6:
e005334. DOI:10.1161/JAHA.116.005334.)
Key Words: acute coronary syndromes • myocardial infarction • risk stratiﬁcation • troponin
T he relationship between baseline levels of troponin orcreatine kinase-MB and outcomes among patients with
non-ST-segment elevation acute coronary syndromes (NSTE
ACS) is established.1 This relationship has not been well
studied in medically managed NSTE ACS populations in the
era of modern antithrombotic therapy that includes
systematic use of more potent P2Y12 inhibition as a
component of dual antiplatelet therapy. In addition, whether
the effect of treatment with a more potent P2Y12 antagonist
(eg, prasugrel versus clopidogrel) is inﬂuenced by degree of
biomarker elevation, particularly among medically managed
patients, is unknown. Although the relationship of troponin
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elevation at baseline with outcome is strong over the ﬁrst
30 days post-ACS, it becomes weaker over longer durations
of follow-up.2,3 The TRILOGY ACS (Targeted Platelet Inhibition
to Clarify the Optimal Strategy to Medically Manage Acute
Coronary Syndromes) trial database provided the opportunity
to explore these important issues in a medically managed
NSTE ACS population treated with long-term dual antiplatelet
therapy.
In a substudy of TRILOGY ACS, the Platelet Function
Substudy, evaluation of platelet reactivity measured by serial
P2Y12 reaction unit (PRU) assessment showed more potent
platelet inhibition with prasugrel compared with clopidogrel.4
There was no relationship between platelet reactivity and
ischemic outcomes or differential treatment effect according
to platelet reactivity. The relationship between peak troponin
level, platelet reactivity, outcomes, and treatment effect has
not been explored. The Platelet Function Substudy provided
an opportunity to examine these relationships.
Methods
Data Source
The study design and primary results of TRILOGY ACS were
previously published.5 Brieﬂy, TRILOGY ACS was a multina-
tional, double-blind, double-dummy, randomized active con-
trolled trial that compared the effects of prasugrel versus
clopidogrel among patients with NSTE ACS who were
medically managed without revascularization. The trial was
conducted between June 2008 and September 2011 at 966
centers worldwide. The primary end point was a composite of
death from cardiovascular causes, nonfatal myocardial infarc-
tion (MI), or nonfatal stroke at 30-month follow-up. The trial
was approved by the institutional review board or ethics
committee of all participating sites, and all participants
provided written informed consent prior to enrollment. The
current analyses were approved by the Duke University
Medical Center Institutional Review Board with waiver of
informed consent and HIPAA (Health Insurance Portability and
Accountability Act of 1996) authorization.
Patient Characteristics and Study Deﬁnitions
TRILOGY ACS randomized 9326 patients. For this secondary
analysis, we identiﬁed 6763 patients (72.5% of the intention-
to-treat population) for whom peak troponin (T or I) data were
available within 48 hours of the index event. Troponin I was
used twice as often as troponin T. Patients were excluded if
they had recurrent MI, bypass surgery, or percutaneous
coronary intervention between the index event presentation
and the reported peak cardiac troponin value. The analysis of
platelet function included only patients enrolled in the Platelet
Function Substudy who had peak troponin data available
(n=1810/2564 [70.6%]).
End Points
Efﬁcacy outcomes of interest in this secondary analysis were
the following: (1) 30-month cardiovascular death, MI, or
stroke (primary efﬁcacy end point of TRILOGY ACS); (2) 30-
month cardiovascular death or MI; (3) 30-month rates of the
individual components cardiovascular death, MI, and stroke;
and (4) 30-month all-cause death.
Statistical Methods
Because multiple troponin assays were used across the 966
sites in TRILOGY ACS, we normalized site-laboratory-based
peak troponin values as a ratio of the site-reported upper limit
of normal (ULN) for the assay used. Patients were grouped by
categories of peak troponin/ULN ratio (<19ULN; 1 to
<39ULN; 3 to <59ULN; ≥59ULN). Peak troponin ratios
were truncated to the 98th percentile for statistical analysis.
For this study, peak troponin was the highest value measured
within 48 hours of the index event.
Baseline patient characteristics, including demographics,
clinical characteristics, GRACE (Global Registry of Acute
Coronary Events) risk score, and concomitant medications at
randomization, were summarized according to peak troponin
ratio. The GRACE score is a risk-stratiﬁcation tool developed
to estimate the risk of in-hospital and 6-month mortality
among all patients hospitalized with ACS. The risk score was
created from a risk-prediction model developed using an
international ACS registry database.6 Continuous variables
are presented as medians (25th, 75th percentiles), and
differences were compared using the Kruskal–Wallis test.
Categorical variables are presented as counts (percentages),
and differences were compared using the Pearson v2 or
Fisher exact test if cell frequencies were not sufﬁcient.
For each ischemic outcome, the total number of events
and Kaplan–Meier event rates at 30 months after random-
ization (95% CI) were presented according to peak troponin
category. Time-to-event is deﬁned as the time from random-
ization to the onset of the end point. Time-to-ﬁrst-event for a
composite end point is deﬁned as the time from randomiza-
tion to the occurrence of the ﬁrst event of the composite end
point. Censoring rules are deﬁned in Tables S1 and S2. Event
rates across the follow-up period were compared using the
log-rank test.
To examine the relationship between peak troponin level
and clinical outcomes, unadjusted and adjusted Cox propor-
tional hazards regression models were developed to test the
univariable and multivariable associations of continuous peak
troponin ratios with each clinical outcome. TRILOGY ACS
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models previously built for each ischemic outcome were used
to adjust for baseline characteristics and risk factors. The
proportional hazards assumption was checked for each
variable, and the linearity assumption was checked for each
continuous variable. If the proportional hazards assumption
was violated, an interaction of the variable with log-
transformed time was included in the model. If the linearity
assumption was violated, a linear or restricted cubic spline
was used to approximate the nonlinear relationship of the
variable with the outcome.7 In cases where the peak troponin
ratio was found to have a nonlinear relationship with a given
end point, it was modeled using a linear spline with a knot
point at 3.09ULN, which was determined via numerical
simulation across the range of all peak troponin ratios. For
further details, please see Table S3. A full description of the
TRILOGY ACS adjustment models used in this analysis is
provided in Data S1 and Table S4.
The interaction between peak troponin level, study treat-
ment (prasugrel versus clopidogrel), and ischemic outcomes
was also computed. Further assessment of this relationship
was completed in a subgroup of patients who underwent
coronary angiography prior to randomization, eliminating
those without angiographically proven coronary disease
(lesion causing >50% stenosis).
Baseline characteristics of patients in the Platelet Function
Substudy sample were summarized according to peak
troponin ratio category. For these patients, the unadjusted
and adjusted associations of peak troponin ratio with 30-day
PRU values and the interaction with study treatment were
evaluated. To gauge the strength of the linear relationship
between peak troponin ratio and 30-day PRU values, the
Pearson correlation coefﬁcient was computed and the null
hypothesis of zero correlation was tested.
All analyses were conducted using SAS statistical software
version 9.4 (SAS Institute, Cary, NC). A P value of <0.05
(2-sided) was considered statistically signiﬁcant. No adjust-
ments were made for multiple comparisons.
Results
Overall Study Sample
Baseline characteristics of the 6763 patients who had
sufﬁcient laboratory data reported to determine the peak
troponin ratio at 48 hours compared with the 2563 patients
who were excluded are provided in Table S5. Baseline
characteristics of the 6763 patients included are shown by
peak troponin ratio categories in Table 1. Patients with peak
troponin ratios <19ULN were younger, more often women,
more often from Central/Eastern Europe, and had lower
GRACE risk scores than patients in other troponin groups.
Patients with ratios ≥59ULN more frequently smoked but
less often had prior MI or percutaneous coronary intervention.
Diabetes mellitus prevalence, body mass index, and hemo-
globin were similar across groups. Although there was a
statistically signiﬁcant difference in serum creatinine across
troponin groups, absolute differences were small and unlikely
to be clinically relevant.
Ischemic Outcomes According to Peak Troponin
Table 2 shows the number of 30-month ischemic outcome
events and Kaplan–Meier event rates across peak troponin
categories. Figure 1 displays corresponding Kaplan–Meier
event rate curves. Trends for increasing event rates with
increasing peak troponin ratios were statistically signiﬁcant for
all end points. The relationship was linear for 30-month all-
cause mortality but appeared to increase and then plateau at
peak troponin ratios ≥39ULN for the composite end points. The
greatest difference in event rates was between peak troponin
ratios <19ULN and any peak troponin ratio ≥19ULN during
early follow-up. Through 30 months, event rates for patients
with peak troponin ratios ≥59ULN were more than twice as
high as rates for patients with peak troponin ratios <19ULN.
Table 3 displays unadjusted and adjusted hazard ratios for
30-month ischemic outcomes per unit increase in peak
troponin ratio, modeled as a linear spline. The graphic
representation of this relationship for the primary efﬁcacy
end point is displayed in Figure S1A and S1B. In unadjusted
analyses, increases in peak troponin ratio were strongly
associated with each outcome up to 39ULN; beyond this, the
risk of ischemic events remained relatively constant as peak
troponin ratios increased. Results were consistent after
adjustment for baseline characteristics, except that the
association with cardiovascular death was no longer signiﬁ-
cant. Note, the upper segment of the troponin linear spline
(ratios >39ULN) is not presented in Table 3 as all associa-
tions with outcomes are nonsigniﬁcant.
Table 3 also shows that there were no statistically
signiﬁcant interactions between peak troponin ratio and
study treatment for any of the ischemic outcomes. The
graphic representation of this relationship is displayed in
Figure S2. In a subgroup analysis assessing this relationship
among patients with angiographically proven coronary dis-
ease, the interaction between peak troponin ratio, study
treatment, and either combined end point or all-cause
mortality also lacked statistical signiﬁcance. These results
remained unchanged after adjustment for time from patient
presentation to administration of study drug.
Peak Troponin and Platelet Function
Among patients enrolled in the TRILOGY ACS Platelet Function
Substudy, 1810 (70.6%) had necessary measurements to
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Table 1. Baseline Characteristics According to 48-Hour Peak Troponin Level
Peak Troponin Level as Ratio of ULN
P Value<1x (N=1574) 1x to <3x (N=1203) 3x to <5x (N=581) ≥5x (N=3405)
Demographics
Age, y 65.0 (58.0, 72.0) 67.0 (58.0, 75.0) 67.0 (60.0, 75.0) 67.0 (60.0, 76.0) <0.001
Age ≥75 y 285/1574 (18.1%) 301/1203 (25.0%) 156/581 (26.9%) 954/3405 (28.0%) <0.001
Weight, kg 75.0 (65.0, 86.0) 75.0 (65.0, 89.0) 75.0 (65.0, 86.0) 77.0 (66.0, 89.0) 0.008
Weight <60 kg 211/1573 (13.4%) 191/1201 (15.9%) 78/581 (13.4%) 426/3401 (12.5%) 0.033
Sex 0.004
Female 648/1574 (41.2%) 466/1203 (38.7%) 223/581 (38.4%) 1221/3405 (35.9%)
Male 926/1574 (58.8%) 737/1203 (61.3%) 358/581 (61.6%) 2184/3405 (64.1%)
Region <0.001
Central/Eastern Europe 714/1574 (45.4%) 354/1203 (29.4%) 195/581 (33.6%) 798/3405 (23.4%)
East Asia 180/1574 (11.4%) 110/1203 (9.1%) 42/581 (7.2%) 246/3405 (7.2%)
Indian subcontinent 147/1574 (9.3%) 140/1203 (11.6%) 43/581 (7.4%) 149/3405 (4.4%)
Latin America 175/1574 (11.1%) 142/1203 (11.8%) 61/581 (10.5%) 381/3405 (11.2%)
Mediterranean basin 103/1574 (6.5%) 86/1203 (7.1%) 32/581 (5.5%) 318/3405 (9.3%)
North America 132/1574 (8.4%) 190/1203 (15.8%) 99/581 (17.0%) 821/3405 (24.1%)
Western
Europe/Scandinavia
112/1574 (7.1%) 158/1203 (13.1%) 95/581 (16.4%) 604/3405 (17.7%)
Rest of world 11/1574 (0.7%) 23/1203 (1.9%) 14/581 (2.4%) 88/3405 (2.6%)
Presentation characteristics
Hours from presentation to
start of study drug
83.3 (45.5, 141.4) 109.0 (64.8, 159.2) 109.7 (69.2, 158.4) 118.0 (72.3, 165.8) <0.001
Killip class II–IV
on presentation
129/1572 (8.2%) 148/1202 (12.3%) 81/581 (13.9%) 467/3404 (13.7%) <0.001
Disease classification <0.001
Unstable
angina/unknown
1291/1574 (82.0%) 165/1203 (13.7%) 0/581 (0.0%) 0/3405 (0.0%)
NSTEMI 283/1574 (18.0%) 1038/1203 (86.3%) 581/581 (100.0%) 3405/3405 (100.0%)
Medical history
Family history of CAD 421/1402 (30.0%) 361/1070 (33.7%) 162/522 (31.0%) 1064/2984 (35.7%) 0.002
Hypertension 1347/1570 (85.8%) 991/1201 (82.5%) 491/581 (84.5%) 2720/3393 (80.2%) <0.001
Hyperlipidemia 925/1482 (62.4%) 711/1164 (61.1%) 334/565 (59.1%) 2175/3304 (65.8%) 0.001
Diabetes mellitus 598/1574 (38.0%) 488/1201 (40.6%) 244/581 (42.0%) 1309/3396 (38.5%) 0.214
Current/recent
smoking*
268/1558 (17.2%) 231/1192 (19.4%) 119/573 (20.8%) 826/3363 (24.6%) <0.001
Prior MI 697/1566 (44.5%) 559/1194 (46.8%) 260/576 (45.1%) 1408/3366 (41.8%) 0.016
Prior PCI 521/1569 (33.2%) 422/1196 (35.3%) 176/578 (30.4%) 795/3372 (23.6%) <0.001
Prior CABG 261/1572 (16.6%) 218/1203 (18.1%) 90/580 (15.5%) 632/3390 (18.6%) 0.149
Prior PAD 92/1552 (5.9%) 89/1175 (7.6%) 43/572 (7.5%) 302/3333 (9.1%) 0.002
Prior atrial fibrillation 126/1533 (8.2%) 106/1175 (9.0%) 50/565 (8.8%) 263/3296 (8.0%) 0.685
Prior heart failure 304/1565 (19.4%) 178/1194 (14.9%) 98/576 (17.0%) 400/3376 (11.8%) <0.001
Prior stroke 7/1571 (0.4%) 4/1198 (0.3%) 4/578 (0.7%) 24/3385 (0.7%) 0.414
Continued
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compute peak troponin/ULN ratios. Baseline characteristics
by peak troponin ratio category are shown in Table S6.
Compared with other groups, patients with peak troponin
ratios <1xULN were younger, more often from Central/Eastern
Europe, and less likely to be current/prior smokers or have a
family history of coronary artery disease or hyperlipidemia.
Additionally, they were less likely to have undergone angiog-
raphy prior to randomization. Diabetes mellitus prevalence was
similar across groups.
As displayed in Figure 2, there was no relationship
between peak troponin and PRU among patients with
angiographically proven coronary artery disease. Results
remain unchanged even after adjustment for age group
(≥75 years versus <75 years), clopidogrel stratum at ran-
domization, randomized treatment assignment, and time from
patient presentation to start of study drug.
Discussion
This analysis of TRILOGY ACS demonstrated that among NSTE
ACS patients selected for medical management, including
dual antiplatelet therapy with a P2Y12 antagonist, there was a
graded relationship of increasing peak troponin with long-term
ischemic events. Event rates at 30 months for patients with
troponin ≥59ULN were more than twice those for patients
with peak troponin <19ULN. There was no apparent
Table 1. Continued
Peak Troponin Level as Ratio of ULN
P Value<1x (N=1574) 1x to <3x (N=1203) 3x to <5x (N=581) ≥5x (N=3405)
Baseline risk assessment
GRACE risk score 116.0 (101.0, 130.0) 122.0 (106.0, 141.0) 128.0 (112.0, 147.0) 124.0 (108.0, 144.0) <0.001
Body mass index, kg/m2 27.0 (24.5, 30.5) 27.2 (24.2, 31.0) 27.2 (24.6, 30.8) 27.3 (24.4, 30.8) 0.485
Systolic blood pressure, mm Hg 130.0 (120.0, 140.0) 130.0 (117.0, 140.0) 126.0 (118.0, 138.0) 125.0 (115.0, 138.0) <0.001
Heart rate, bpm 68.5 (62.0, 76.0) 69.0 (62.0, 76.0) 68.0 (60.0, 76.0) 69.0 (62.0, 76.0) 0.491
Hemoglobin, g/dL 13.6 (12.6, 14.6) 13.4 (12.3, 14.5) 13.6 (12.4, 14.7) 13.5 (12.4, 14.7) 0.104
Serum creatinine, mg/dL 1.0 (0.8, 1.1) 1.0 (0.8, 1.2) 1.0 (0.9, 1.2) 1.0 (0.8, 1.2) <0.001
At randomization
Treatment 0.323
Prasugrel 767/1574 (48.7%) 585/1203 (48.6%) 276/581 (47.5%) 1725/3405 (50.7%)
Clopidogrel 807/1574 (51.3%) 618/1203 (51.4%) 305/581 (52.5%) 1680/3405 (49.3%)
Clopidogrel strata <0.001
No clopidogrel 123/1574 (7.8%) 36/1203 (3.0%) 22/581 (3.8%) 92/3405 (2.7%)
Clopidogrel started in hospital ≤72 hours 905/1574 (57.5%) 798/1203 (66.3%) 421/581 (72.5%) 2759/3405 (81.0%)
Home clopidogrel 546/1574 (34.7%) 369/1203 (30.7%) 138/581 (23.8%) 554/3405 (16.3%)
Prerandomization procedures
Angiography performed 555/1574 (35.3%) 568/1203 (47.2%) 256/581 (44.1%) 1941/3405 (57.0%) <0.001
Concomitant medications at randomization
Aspirin daily dose
<100 mg 470/1574 (29.9%) 406/1203 (33.7%) 182/581 (31.3%) 1116/3405 (32.8%) 0.112
100 to 250 mg 943/1574 (59.9%) 628/1203 (52.2%) 308/581 (53.0%) 1658/3405 (48.7%) <0.001
>250 mg 86/1574 (5.5%) 89/1203 (7.4%) 56/581 (9.6%) 396/3405 (11.6%) <0.001
b-Blocker 1248/1574 (79.3%) 947/1203 (78.7%) 468/581 (80.6%) 2753/3405 (80.9%) 0.339
ACE-I/ARB 1173/1574 (74.5%) 883/1203 (73.4%) 446/581 (76.8%) 2635/3405 (77.4%) 0.018
Statin 1287/1574 (81.8%) 1016/1203 (84.5%) 482/581 (83.0%) 2945/3405 (86.5%) <0.001
Proton pump inhibitor 355/1574 (22.6%) 308/1203 (25.6%) 185/581 (31.8%) 982/3405 (28.8%) <0.001
Data presented as n/N (%) or median (25th, 75th percentile). ACE-I/ARB indicates angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; bpm, beats per minute; CABG,
coronary artery bypass graft; CAD, coronary artery disease; GRACE, Global Registry of Acute Coronary Events; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial
infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; ULN, upper limit of normal.
*Smoking within 30 days of randomization.
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incremental beneﬁt of treatment with prasugrel versus
clopidogrel according to peak troponin ratio among medically
managed patients with NSTE ACS.
Peak Troponin and Long-Term Outcomes
Since the introduction of troponin testing in the early 1990s,
its role has evolved from MI diagnosis to include risk
stratiﬁcation following ACS. It is known from previous
analyses, including FRISC (Fragmin during Instability in
Coronary Artery Disease) and TACTICS-TIMI 18 (Treat Angina
with Aggrastat and Determine Cost of Therapy with an
Invasive or Conservative Strategy—Thrombolysis in Myocar-
dial Infarction 18) that patients with NSTE ACS who have
troponin elevations above the ULN at admission are at higher
risk for death and recurrent ischemic events.2,8,9 Further-
more, through additional analyses of trials such as GUSTO
(Global Use of Strategies to Open Occluded Coronary
Arteries) IIa, there is a well-characterized relationship between
the magnitude of troponin elevation and outcomes among
patients with NSTE ACS.1 Troponin elevation can also identify
which patients are most likely to beneﬁt from aggressive
antithrombotic therapy and an early invasive strategy.8,9
Recently, a secondary analysis of the TRACER (Thrombin
Receptor Antagonist for Clinical Event Reduction in Acute
Coronary Syndrome) trial, a study designed to examine the
effect of vorapaxar (a protease-activated receptor-1 antago-
nist) versus placebo in NSTE ACS, identiﬁed a differential
relationship between the magnitude of troponin elevation and
2-year mortality among patients treated with and without
revascularization. In a subset of patients included in TRACER
who did not undergo revascularization, increasing levels of
peak cardiac troponin were associated with increasing long-
term mortality (P=0.001). This relationship was not observed
in those who underwent revascularization (P=0.23).10
The graded relationship of increasing peak troponin with
ischemic events that we observed was consistent with this
observation and prior studies evaluating troponin elevation as
a prognostic indicator among patients with NSTE ACS.
However, TRILOGY ACS provided the unique opportunity to
establish this relationship over a long-term (30-month) follow-
up period among patients who were medically managed with
P2Y12 inhibitor therapy. Thus, the results of this analysis
extend our understanding of the relationship of troponin with
risk to long-term follow-up in the important population of
medically managed NSTE ACS patients in the contemporary
Table 2. Thirty-Month Ischemic Event Rates According to 48-Hour Peak Troponin Level
Peak Troponin Level as Ratio of ULN
P Value*<1x (n=1574) 1x to <3x (n=1203) 3x to <5x (n=581) ≥5x (n=3405)
Cardiovascular death, MI, or stroke <0.001
No. of events 118 172 104 607
KM event rate (95% CI) 11.3 (9.1–13.5) 18.4 (15.3–21.4) 26.6 (20.9–32.3) 25.1 (23.0–27.1)
Cardiovascular death <0.001
No. of events 62 80 41 297
KM event rate (95% CI) 5.8 (4.2–7.3) 9.6 (7.0–12.3) 10.8 (6.6–15.0) 12.8 (11.1–14.4)
Myocardial infarction <0.001
No. of events 63 102 72 364
KM event rate (95% CI) 6.4 (4.6–8.1) 10.4 (8.4–12.4) 17.6 (13.1–22.0) 15.6 (13.8–17.3)
Cardiovascular death or MI <0.001
No. of events 111 157 97 569
KM event rate (95% CI) 10.6 (8.5–12.8) 16.8 (13.8–19.8) 25.0 (19.4–30.6) 23.5 (21.4–25.5)
Stroke 0.005
No. of events 11 22 8 67
KM event rate (95% CI) 1.2 (0.4–2.0) 2.8 (1.5–4.1) 1.8 (0.5–3.2) 3.3 (2.4–4.3)
All-cause death <0.001
No. of events 83 102 60 362
KM event rate (95% CI) 7.3 (5.7–9.0) 11.8 (9.1–14.5) 14.7 (10.3–19.0) 14.8 (13.2–16.5)
KM indicates Kaplan–Meier; MI, myocardial infarction; No., number; ULN, upper limit of normal.
*Two-sided P value based on the log-rank test.
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Figure 1. Cumulative Kaplan–Meier estimates of 30-month ischemic outcomes by 48-hour peak troponin elevation. For
visualization of the numerical results presented in Table 2, Kaplan–Meier failure curves are presented for each efﬁcacy end point.
See Table 2 for relevant log-rank P values. MI indicates myocardial infarction; ULN, upper limit of normal.
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era of more potent P2Y12 inhibitor therapy. Our analyses
demonstrate that despite advances in other medical therapy
acutely and in secondary prevention, higher peak troponin
values portend worse ischemic outcomes.
Peak Troponin and Effect of More Potent
Antiplatelet Therapy
Substudies of several randomized clinical trials showed that
the treatment effect of glycoprotein IIb/IIIa antagonists was
ampliﬁed among patients with baseline troponin elevation, but
there was no evident beneﬁt among those without.11–13 These
ﬁndings were consistent across studies despite signiﬁcant
differences in patient populations, highlighting the importance
of troponin elevation in identifying high-risk patients who may
beneﬁt from more potent antiplatelet therapy.11 Given these
observations and our results correlating troponin and rates of
adverse cardiovascular events, it might be anticipated that
higher-risk medically managed patients with greater peak
troponin levels would also beneﬁt preferentially from more
potent antiplatelet therapy. However, we observed no such
interaction of peak troponin level with more potent dual
antiplatelet therapy among patients assigned to prasugrel
compared with clopidogrel. This was consistent among the
subset of patients with angiographically proven coronary
disease who were medically managed in TRILOGY ACS. Thus,
it is unlikely that inclusion of patients with troponin elevation
unrelated to atherosclerotic coronary disease signiﬁcantly
inﬂuenced our analysis.
A number of considerations may contribute to our observa-
tions. Because this is a secondary analysis, it was not powered
to detect an effect of more potent P2Y12 inhibition according to
peak troponin values. Further, whereas the PARAGON-B
(Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary
syndrome events in a Global Organization Network B) study
assessed a glycoprotein IIb/IIIa inhibitor (steady-state platelet
aggregation inhibition >90%) versus placebo, neither prasugrel
(50%) nor clopidogrel (30%) achieve that level of platelet
aggregation inhibition, and they were compared head-to-head
instead of against placebo.14,15 Together these features of trial
design may have contributed to the differential ﬁndings.
Additionally, participants in TRILOGY ACS were randomized to
prasugrel or clopidogrel 4.5 days after their index clinical
event and could be enrolled up to 10 days after the index
event.5 It is possible that the beneﬁt of more potent antiplatelet
therapy may be related to the timing of therapy initiation
relative to myocardial ischemia onset (which was much earlier
in PARAGON-B), and particularly that patients with completed
infarction by this time point may not beneﬁt from more potent
antiplatelet therapy. Additionally, prior evaluations of more
potent antiplatelet therapies primarily focused on patients who
underwent an invasive treatment strategy. It is possible that the
beneﬁt of more potent antiplatelet therapy seen in prior studies
may have been derived from reduced periprocedural adverse
ischemic outcomes. Finally, it is possible that bleeding
complications may have attenuated the beneﬁt of more potent
antiplatelet therapy.
Peak Troponin and Platelet Reactivity
A substudy of TRILOGY ACS evaluated the effects of prasugrel
and clopidogrel on serial PRU assessments. This analysis
revealed lower platelet reactivity with prasugrel compared
with clopidogrel; however, there was no difference in ischemic
outcomes by treatment assignment.4,5 Our exploratory anal-
ysis of the TRILOGY ACS Platelet Function Substudy revealed
that the effect of treatment on platelet inhibition (as assessed
by 30-day PRU values) did not vary substantially based on
peak troponin value.
Strengths and Limitations
This secondary analysis of TRILOGY ACS demonstrates a
novel correlation between troponin elevation and prognosis in
a study sample selected for medical management of NSTE
ACS. One of the strengths of our analysis is that it used data
Table 3. Unadjusted and Adjusted Hazard Ratios for 30-Month Ischemic Outcomes According to 48-Hour Peak Troponin Elevation
Unadjusted HR (95% CI)* Adjusted HR (95% CI)*
Peak Troponin9Treatment
Interaction P Value
Cardiovascular death, MI, stroke 1.350 (1.263–1.442) 1.182 (1.066–1.311) 0.483
Cardiovascular death or MI 1.347 (1.257–1.443) 1.183 (1.062–1.318) 0.433
Cardiovascular death 1.291 (1.175–1.419) 1.090 (0.942–1.263) 0.371
Myocardial infarction 1.411 (1.292–1.541) 1.238 (1.081–1.419) 0.413
Stroke 1.387 (1.136–1.695) 0.998 (0.996–1.001)† 0.191
All-cause mortality 1.282 (1.179–1.393) 1.001 (1.000–1.001)† 0.234
HR indicates hazard ratio; MI, myocardial infarction.
*Per 1 unit increase in peak troponin/upper limit of normal ratio.
†Peak troponin elevation modeled linearly as the assumption of linearity was satisﬁed.
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collected as part of a large, multinational, randomized trial,
which enhances data consistency and eliminates bias in the
assessment of overall treatment effects. Because of the large
number of subjects, the results are statistically robust.
However, because these results are drawn from a patient
population selected for a randomized clinical trial, they may
not be generalizable to the broader population of medically
managed patients in general practice. Troponin values used
for our analysis were collected up to 48 hours after presen-
tation, consistent with contemporary clinical practice. It is
possible that by limiting our analysis to values within
48 hours of presentation, a higher peak value could have
been missed, but this rule was applied consistently to all
patients. Peak troponin data within 48 hours were not
available in about 25% of study participants, eliminating this
group from our analysis. Although there were differences
between those included or not, most were modest and would
not be expected to alter the relationships we observed
(Table S5). Troponin assays were not standardized across
participating sites. Thus, they reﬂect a wide variety of
individual assays with variable assay performance character-
istics, and potentially varying site-speciﬁc ULNs for the same
assay. However, this reﬂects the state of actual clinical
practice, and we attempted to account for this by normalizing
the reported values using a ratio of the reported value to the
ULN reported for the assay. This variability and resultant
“noise” introduced would be expected to result in an
underestimation of the relationship between increasing
troponin level and outcomes. Additionally, it is possible that
some patients with elevated troponin levels who were
included in TRILOGY ACS did not have signiﬁcant coronary
artery disease. In this case, the true association of troponin
with long-term ischemic outcomes may have been underes-
timated. Of the patients who underwent angiography, how-
ever, very few had absence of obstructive coronary disease,
and when we excluded those patients from our analyses,
there were no differences in our ﬁndings. Although designed
to evaluate medically managed patients, a small number of
patients (7.1%) underwent postindex revascularization at a
median of 120.5 days after the index event. Because of the
infrequency of downstream revascularization in our study
sample and that it occurred late relative to the time of
troponin sampling, we believe the commitment to an initial
medical management strategy was met and that it is unlikely
that our results were signiﬁcantly affected. Finally, it is
possible that because we deﬁned peak troponin using values
collected within 48 hours after the index event, the true peak
troponin value was missed. However, it is important to note
that the impact of missing the true peak would tend to
underestimate the relationship between peak troponin level
Figure 2. Forty-eight-hour peak troponin ratio and 30-day platelet reactivity unit (PRU). For patients
enrolled in the Platelet Function Substudy, a box plot is used to assess the unadjusted association of peak
troponin elevation with 30-day PRU, as well as the interaction with study treatment (P<0.001). ULN
indicates upper limit of normal.
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and adverse outcomes. Despite its limitations, our analysis
shows the prognostic importance of higher levels of troponin
for long-term outcomes among medically managed patients
with NSTE ACS, even in the setting of treatment with modern,
potent antiplatelet agents, and the effect is not related to the
degree of platelet inhibition as assessed by the P2Y12 assay.
Conclusion
Among NSTE ACS patients selected for medical management,
there was a graded relationship of increasing peak troponin
with long-term ischemic events, but no heterogeneity of
treatment effect for prasugrel versus clopidogrel (clinical or
PRU-based) according to 48-hour peak troponin level.
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Data S1. 
 
TRILOGY ACS Adjustment Models 
 
TRILOGY ACS Efficacy Adjustment Models 
The TRILOGY ACS efficacy outcome adjustment models were constructed using a comprehensive list of patient 
characteristics and risk factors selected based on clinical knowledge (for a complete list, see the table below). Missing 
values were imputed using a multiple imputation approach that applies an MCMC method to create a monotone missing 
pattern and then uses a multivariate normal distribution to impute missing values. The imputation method replaces each 
missing value with a representative sample of plausible values by creating m complete data sets. As a result, the 
uncertainty due to the missingness is appropriately accounted for and analyses on the imputed data result in valid 
statistical inference. The m complete data sets can be analyzed using standard statistical procedures; the results are then 
aggregated across all simulated data sets. In this work, m was taken to be 25. Because a comparison of descriptive 
statistics from the first complete data set and the aggregation of the 25 complete data sets revealed negligible differences, 
only the first complete data set was used when fitting the adjustment for ease of computation. When fitting the adjustment 
model, the proportional hazards assumption was checked for each covariate and the linearity assumption was checked for 
each continuous covariate at alpha-level 0.05. If the proportional hazard assumption was violated, an interaction of the 
variable with log-transformed time was included in the model. If the linearity assumption was violated, a restricted cubic 
spline was used to approximate the non-linear relationship of the variable with the outcome. All analyses were performed 
using SAS 9.3 (SAS Institute Inc., Cary, NC) and R 2.14.1 (R Foundation for Statistical Computing, Vienna, Austria). 
 
Table S4 details the composition of each adjustment model. 
 
TRILOGY ACS Bleeding Adjustment Models 
The TRILOGY ACS bleeding outcome adjustment models were constructed using a comprehensive list of patient 
characteristics and risk factors selected based on clinical knowledge (for a complete list, see Table S4). Missing values 
were imputed using a multiple imputation approach that applies an MCMC method to create a monotone missing pattern 
and then uses a multivariate normal distribution to impute missing values. The imputation method replaces each missing 
value with a representative sample of plausible values by creating m complete data sets. As a result, the uncertainty due to 
the missingness is appropriately accounted for and analyses on the imputed data result in valid statistical inference. The m 
complete data sets can be analyzed using standard statistical procedures; the results are then aggregated across all 
simulated data sets. In this work, m was taken to be 25. Because a comparison of descriptive statistics from the first 
complete data set and the aggregation of the 25 complete data sets revealed negligible differences, only the first complete 
data set was used when fitting the adjustment for ease of computation. When fitting the adjustment model, the 
proportional hazards assumption was checked for each covariate and the linearity assumption was checked for each 
continuous covariate at alpha-level 0.05. If the proportional hazard assumption was violated, an interaction of the variable 
with time was included in the model. If the linearity assumption was violated, a restricted cubic spline was used to 
approximate the non-linear relationship of the variable with the outcome. All analyses were performed using SAS 9.3 
(SAS Institute Inc., Cary, NC) and R 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria) 
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 Table S1. Censoring scheme for the primary endpoint (cardiovascular death, myocardial infarction, or stroke) and for 
nonfatal secondary endpoints 
Scenario  Censoring Rule 
Completed final study visit Final visit date (date of study termination / last 
contact on end-of-study case report form page 
unless type of visit = 95) 
Death during follow-up Adjudicated death date  
Withdrew consent  Date withdrew consent 
No final visit and did not withdraw consent Last onsite or telephone visit date 
Vital status only alive Last onsite or telephone visit date  
Vital status only died  Last onsite or telephone visit date  
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Table S2. Censoring scheme for cardiovascular death or for all-cause death 
Scenario  Censoring Rule 
Completed final study visit Final visit date (date of study termination / last contact 
on end-of-study page unless type of visit = 95) 
Death during follow-up Adjudicated death date 
Withdrew consent  Date withdrew consent 
No final visit and did not withdraw consent Last date when vital status is known 
Vital status only alive Last date when vital status is known  
Vital status only died (without adjudication of a COD) Death date (if available) 
Vital status only died (with adjudication of a COD)  Adjudicated death date 
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Table S3. Descriptive statistics for troponin 
 Troponin I Troponin T Troponin 
N 4796 2185 6763 
Median time (Q1, Q3) from initial to peak 
sample value* 
11.25 
(7.00, 16.98) 
11.88 
(7.00, 19.42) 
11.36 
(7.00, 17.55) 
Peak ratio percentiles    
   100% Max 448222.22 6000.00 448222.22 
     99% 1082.00 318.18 900.00 
     98% 609.75 237.86 506.25 
     97% 462.10 165.00 362.22 
     96% 351.00 132.14 290.00 
     95% 293.25 116.00 240.00 
     90% 143.00 59.46 115.67 
     75% Q3 36.45 17.60 28.90 
     50% Median  5.50 3.57 5.00 
     25% Q1 1.10 0.90 1.00 
     0% Min <0.01 <0.01 <0.01 
*Time (in hours) from initial to peak sample value within 48 hours after index presentation. Calculated from samples 
with non-missing initial and peak date/times.
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Table S4. TRILOGY ACS Efficacy and Bleeding Adjustment Models 
Characteristic CVD/MI/Stroke CVD MI Stroke 
All-Cause 
Death 
GUSTO Severe / 
LT / Moderate 
Bleeding (non-
CABG) 
TIMI Major/ 
Minor 
Bleeding 
(non-CABG) 
   Randomized Treatment      - - 
   Weight (kg)        
   Age (y)      * * 
   Female sex        
   NSTEMI        
   Killip class I on presentation        
   Time from presentation to study drug start 
(h) 
       
   Cardiovascular risk factors:        
           Family history of CAD      - - 
           Hypertension      - - 
           Hyperlipidemia      - - 
           Diabetes Mellitus      - - 
           Current/recent smoke      - - 
           Previous peptic ulcer disease - - - - -   
   Cardiovascular disease history:        
           Previous myocardial infarction      - - 
           Previous PCI      - - 
           Previous CABG      - - 
           Previous peripheral artery disease        
           Previous atrial fibrillation      - - 
           Previous heart failure      - - 
   At randomization:        
           Systolic blood pressure (mmHg) *   *  *  
           Heart rate (bpm)    *  - - 
           Heart rate*log(time)   - -  - - 
           Clopidogrel stratum 2 – Started in 
hospital ≤72 h 
       
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Characteristic CVD/MI/Stroke CVD MI Stroke 
All-Cause 
Death 
GUSTO Severe / 
LT / Moderate 
Bleeding (non-
CABG) 
TIMI Major/ 
Minor 
Bleeding 
(non-CABG) 
           Clopidogrel stratum 3 – At home        
           Angiography performed?        
           Hemoglobin (g/dL)        
           Hemoglobin (g/dL)*(time) - - - - -  - 
           Creatinine (mg/dL) *  *     
   Baseline concomitant medications:        
           Beta-blocker        
           ACE/ARB      - - 
           Statin      - - 
           PPI      - - 
   Region:        
           East Asia      - - 
           Indian Subcontinent      - - 
           Latin America      - - 
           Mediterranean Basin      - - 
           North America      - - 
           Rest of World      - - 
           Western Europe/Scandinavia      - - 
*A restricted cubic spline was used to account for the non-linear relationship of the variable with the outcome.   
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Table S5. Baseline characteristics of included and excluded study patients 
 Included (N=6763) Excluded (N=2563) P-value  
Demographics    
Age, yrs 66.0 (59.0, 75.0) 64.0 (57.0, 71.0) <0.001 
Age ≥75 yrs 1696/6763 (25.1%) 387/2563 (15.1%) <0.001 
Weight, kg 76.0 (65.0, 88.0) 72.1 (62.0, 83.0) <0.001 
Weight <60 kg 906/6756 (13.4%) 495/2563 (19.3%) <0.001 
Female sex 2558/6763 (37.8%) 1092/2563 (42.6%) <0.001 
Region   <0.001 
Central/Eastern Europe 2061/6763 (30.5%) 1029/2563 (40.1%)  
East Asia 578/6763 (8.5%) 174/2563 (6.8%)  
Indian Subcontinent 479/6763 (7.1%) 662/2563 (25.8%)  
Latin America 759/6763 (11.2%) 517/2563 (20.2%)  
Mediterranean Basin 539/6763 (8.0%) 119/2563 (4.6%)  
North America 1242/6763 (18.4%) 29/2563 (1.1%)  
Western Europe/Scandinavia 969/6763 (14.3%) 25/2563 (1.0%)  
Rest of World 136/6763 (2.0%) 8/2563 (0.3%)  
Presentation characteristics    
Hours from presentation to start of study drug 108.5 (65.5, 159.9) 105.1 (53.2, 157.4) 0.006 
Killip class II–IV on presentation 825/6759 (12.2%) 310/2559 (12.1%) 0.904 
Disease classification   <0.001 
Unstable angina/unknown 1456/6763 (21.5%) 1350/2563 (52.7%)  
NSTEMI 5307/6763 (78.5%) 1213/2563 (47.3%)  
Medical history    
Family history of CAD 2008/5978 (33.6%) 510/2303 (22.1%) <0.001 
Hypertension 5549/6745 (82.3%) 2076/2558 (81.2%) 0.213 
Hyperlipidemia 4145/6515 (63.6%) 1102/2355 (46.8%) <0.001 
Diabetes mellitus 2639/6752 (39.1%) 900/2554 (35.2%) <0.001 
Current/recent smoking* 1444/6686 (21.6%) 400/2542 (15.7%) <0.001 
Prior MI 2924/6702 (43.6%) 1063/2544 (41.8%) 0.110 
Prior PCI 1914/6715 (28.5%) 511/2555 (20.0%) <0.001 
Prior CABG 1201/6745 (17.8%) 253/2558 (9.9%) <0.001 
Prior PAD 526/6632 (7.9%) 154/2523 (6.1%) 0.003 
Prior atrial fibrillation 545/6569 (8.3%) 165/2532 (6.5%) 0.005 
Prior heart failure 980/6711 (14.6%) 649/2554 (25.4%) <0.001 
Prior stroke 39/6732 (0.6%) 8/2555 (0.3%) 0.106 
Baseline risk assessment    
GRACE risk score 122.0 (106.0, 140.0) 119.0 (103.0, 136.0) <0.001 
Body mass index, kg/m2 27.2 (24.4, 30.8) 26.7 (23.8, 29.9) <0.001 
Systolic blood pressure, mmHg 128.0 (117.0, 139.0) 130.0 (120.0, 140.0) <0.001 
Heart rate, bpm 69.0 (61.0, 76.0) 70.0 (62.0, 78.0) <0.001 
Hemoglobin, g/dL 13.5 (12.4, 14.6) 13.6 (12.5, 14.7) 0.115 
Serum creatinine, mg/dL 1.0 (0.8, 1.2) 1.0 (0.8, 1.2) <0.001 
At randomization    
Treatment   0.186 
Prasugrel 3353/6763 (49.6%) 1310/2563 (51.1%)  
Clopidogrel 3410/6763 (50.4%) 1253/2563 (48.9%)  
Clopidogrel strata    <0.001 
1 - No clopidogrel 273/6763 (4.0%) 125/2562 (4.9%)  
2 - Clopidogrel started in-hospital ≤72 hrs 4883/6763 (72.2%) 1630/2562 (63.6%)  
3 - Home clopidogrel 1607/6763 (23.8%) 807/2562 (31.5%)  
Pre-randomization procedures    
Angiography performed 3320/6763 (49.1%) 531/2562 (20.7%) <0.001 
Concomitant medications at randomization    
Aspirin daily dose    
<100 mg 2174/6763 (32.1%) 935/2563 (36.5%) <0.001 
100–250 mg 3537/6763 (52.3%) 1419/2563 (55.4%) 0.008 
>250 mg 627/6763 (9.3%) 46/2563 (1.8%) <0.001 
Beta-blocker 5416/6763 (80.1%) 1835/2563 (71.6%) <0.001 
ACE-I/ARB 5137/6763 (76.0%) 1890/2563 (73.7%) 0.027 
Statin 5730/6763 (84.7%) 2046/2563 (79.8%) <0.001 
Proton pump inhibitor 1830/6763 (27.1%) 514/2563 (20.1%) <0.001 
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*Smoking within 30 days of randomization. 
Data presented as n/N (%) or median (25th, 75th percentile). 
ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CABG, coronary artery bypass graft; CAD, 
coronary artery disease; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PAD, peripheral 
artery disease; GRACE, Global Registry of Acute Coronary Events; PCI, percutaneous coronary intervention. 
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Table S6. Baseline characteristics according to 48-hour peak troponin level in Platelet Function Substudy participants 
Characteristic 
 
Peak troponin level as ratio of ULN P-value 
 <1x 
(N=468) 
1x to <3x 
(N=325) 
3x to <5x 
(N=158) 
≥5x 
(N=856) 
Demographics      
Age, yrs 66.0 (58.5, 72.0) 67.0 (59.0, 75.0) 67.5 (60.0, 74.0) 66.0 (59.0, 74.0) 0.089 
Age ≥75 85/468 (18.2%) 86/325 (26.5%) 39/158 (24.7%) 200/856 (23.4%) 0.034 
Weight, kg 75.0 (65.0, 86.0) 78.0 (65.0, 90.0) 77.1 (67.0, 90.0) 75.0 (65.0, 87.1) 0.188 
Weight <60 kg 64/468 (13.7%) 50/325 (15.4%) 15/158 (9.5%) 123/856 (14.4%) 0.344 
Sex     0.096 
Female 196/468 (41.9%) 132/325 (40.6%) 60/158 (38.0%) 303/856 (35.4%)  
Male 272/468 (58.1%) 193/325 (59.4%) 98/158 (62.0%) 553/856 (64.6%)  
Region     <0.001 
Central/Eastern Europe 206/468 (44.0%) 93/325 (28.6%) 49/158 (31.0%) 144/856 (16.8%)  
East Asia 98/468 (20.9%) 53/325 (16.3%) 16/158 (10.1%) 134/856 (15.7%)  
Indian Subcontinent 50/468 (10.7%) 29/325 (8.9%) 8/158 (5.1%) 58/856 (6.8%)  
Latin America 23/468 (4.9%) 13/325 (4.0%) 17/158 (10.8%) 77/856 (9.0%)  
Mediterranean Basin 15/468 (3.2%) 8/325 (2.5%) 2/158 (1.3%) 26/856 (3.0%)  
North America 46/468 (9.8%) 69/325 (21.2%) 40/158 (25.3%) 284/856 (33.2%)  
Western Europe/Scandinavia 29/468 (6.2%) 47/325 (14.5%) 17/158 (10.8%) 83/856 (9.7%)  
Rest of World 1/468 (0.2%) 13/325 (4.0%) 9/158 (5.7%) 50/856 (5.8%)  
Presentation characteristics      
Hours from presentation to start of study drug 86.9 (44.8, 144.2) 102.3 (68.2, 151.6) 122.2 (73.5, 166.3) 120.2 (70.5, 169.1) <0.001 
Killip class II–IV on presentation 40/467 (8.6%) 37/325 (11.4%) 24/158 (15.2%) 117/856 (13.7%) 0.029 
Disease classification     <0.001 
Unstable angina/unknown 382/468 (81.6%) 41/325 (12.6%) 0/158 (0.0%) 0/856 (0.0%)  
NSTEMI 86/468 (18.4%) 284/325 (87.4%) 158/158 (100.0%) 856/856 (100.0%)  
Medical history      
Family history of CAD 108/395 (27.3%) 107/291 (36.8%) 58/140 (41.4%) 300/788 (38.1%) 0.001 
Hypertension 391/465 (84.1%) 269/324 (83.0%) 142/158 (89.9%) 690/854 (80.8%) 0.036 
Hyperlipidemia 224/414 (54.1%) 205/309 (66.3%) 96/147 (65.3%) 550/832 (66.1%) <0.001 
Diabetes mellitus 175/468 (37.4%) 136/325 (41.8%) 66/158 (41.8%) 319/855 (37.3%) 0.391 
Current/recent smoking* 69/460 (15.0%) 61/321 (19.0%) 32/156 (20.5%) 226/848 (26.7%) <0.001 
Prior MI 200/467 (42.8%) 146/323 (45.2%) 69/155 (44.5%) 366/850 (43.1%) 0.897 
Prior PCI 141/468 (30.1%) 118/323 (36.5%) 40/158 (25.3%) 202/852 (23.7%) <0.001 
Prior CABG 59/467 (12.6%) 56/325 (17.2%) 23/158 (14.6%) 155/854 (18.1%) 0.062 
Prior PAD 14/463 (3.0%) 25/319 (7.8%) 13/156 (8.3%) 61/834 (7.3%) 0.007 
Prior atrial fibrillation 57/452 (12.6%) 32/320 (10.0%) 12/153 (7.8%) 70/840 (8.3%) 0.078 
Prior heart failure 117/462 (25.3%) 55/319 (17.2%) 24/156 (15.4%) 115/848 (13.6%) <0.001 
Prior stroke 2/467 (0.4%) 1/322 (0.3%) 3/157 (1.9%) 5/851 (0.6%) 0.203 
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Characteristic 
 
Peak troponin level as ratio of ULN P-value 
 <1x 
(N=468) 
1x to <3x 
(N=325) 
3x to <5x 
(N=158) 
≥5x 
(N=856) 
Baseline risk assessment      
GRACE risk score 118.0 (101.0, 
134.0) 
124.0 (106.0, 
143.0) 
130.0 (112.0, 
144.0) 
123.0 (108.0, 
143.0) 
<0.001 
Body mass index, kg/m2 26.7 (24.2, 30.5) 27.0 (24.1, 31.1) 27.5 (24.7, 32.0) 27.0 (24.2, 30.6) 0.235 
Systolic blood pressure, mmHg 130.0 (120.0, 
140.0) 
130.0 (118.0, 
140.0) 
126.5 (115.0, 
136.0) 
124.0 (110.0, 
135.0) 
<0.001 
Heart rate, bpm 68.0 (61.0, 75.0) 68.0 (60.0, 75.0) 68.0 (62.0, 77.0) 70.0 (62.0, 77.0) 0.061 
Hemoglobin, g/dL 13.8 (12.8, 14.7) 13.4 (12.4, 14.5) 13.6 (12.5, 14.9) 13.6 (12.5, 14.7) 0.042 
Serum creatinine, mg/dL 1.0 (0.8, 1.1) 1.0 (0.8, 1.2) 1.0 (0.8, 1.2) 1.0 (0.8, 1.2) 0.008 
At randomization      
Treatment     0.577 
Prasugrel 233/468 (49.8%) 158/325 (48.6%) 69/158 (43.7%) 423/856 (49.4%)  
Clopidogrel 235/468 (50.2%) 167/325 (51.4%) 89/158 (56.3%) 433/856 (50.6%)  
Clopidogrel strata     <0.001 
1 - No clopidogrel 28/468 (6.0%) 9/325 (2.8%) 8/158 (5.1%) 33/856 (3.9%)  
2 - Clopidogrel started in-hospital ≤72 hrs 255/468 (54.5%) 217/325 (66.8%) 119/158 (75.3%) 686/856 (80.1%)  
3 - Home clopidogrel 185/468 (39.5%) 99/325 (30.5%) 31/158 (19.6%) 137/856 (16.0%)  
Pre-randomization procedures      
Angiography performed 136/468 (29.1%) 155/325 (47.7%) 77/158 (48.7%) 475/856 (55.5%) <0.001 
Concomitant medications at randomization      
Aspirin daily dose      
<100 mg 180/468 (38.5%) 156/325 (48.0%) 77/158 (48.7%) 342/856 (40.0%) 0.009 
100–250 mg 242/468 (51.7%) 118/325 (36.3%) 58/158 (36.7%) 326/856 (38.1%) <0.001 
>250 mg 17/468 (3.6%) 23/325 (7.1%) 16/158 (10.1%) 119/856 (13.9%) <0.001 
Beta-blocker 363/468 (77.6%) 257/325 (79.1%) 116/158 (73.4%) 674/856 (78.7%) 0.479 
ACE-I/ARB 330/468 (70.5%) 242/325 (74.5%) 118/158 (74.7%) 615/856 (71.8%) 0.566 
Statin 367/468 (78.4%) 278/325 (85.5%) 132/158 (83.5%) 720/856 (84.1%) 0.028 
Proton pump inhibitor 115/468 (24.6%) 81/325 (24.9%) 43/158 (27.2%) 215/856 (25.1%) 0.930 
*Smoking within 30 days of randomization. 
Data presented as n/N (%) or median (25th, 75th percentile). 
ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CABG, coronary artery bypass graft; CAD, coronary artery disease; MI, 
myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PAD, peripheral artery disease; GRACE, Global Registry of Acute 
Coronary Events; PCI, percutaneous coronary intervention.
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Figure S1A. Estimated spline transformation and 95% confidence interval for the relationship of troponin 
elevation and unadjusted rates of cardiovascular death, MI, or stroke through 30 months 
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Figure S1B. Estimated spline transformation and 95% confidence interval for the relationship of troponin 
elevation and adjusted rates of cardiovascular death, MI, or stroke through 30 months 
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Figure S2. Estimated spline transformation and 95% confidence interval for the relationship of troponin 
elevation and adjusted rates of cardiovascular death, myocardial infarction, or stroke through 30 months 
stratified by treatment 
 
0 1 2 3 4 5
5
1
0
1
5
2
0
Predicted Rates of CVD/MI/Stroke through 30 Months
Adjusted, Mean of Covariates, by Randomized Treatment
Peak Troponin Ratio
P
re
d
ic
te
d
 E
v
e
n
t 
R
a
te
 (
%
)
Interaction P = 0.483
Prasugrel
Clopidogrel
 by guest on M
arch 7, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Brown, Harvey D. White, E. Magnus Ohman, Matthew T. Roe and Christian W. Hamm
Sarah A. Goldstein, L. Kristin Newby, Derek D. Cyr, Megan Neely, Thomas F. Lüscher, Eileen B.
Medically Managed Patients With Acute Coronary Syndromes
Term Ischemic Events Among−Relationship Between Peak Troponin Values and Long
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.116.005334
2017;6:e005334; originally published April 11, 2017;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/6/4/e005334
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 by guest on M
arch 7, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
